Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0038362 (stomatitis)
 8,852 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In an open-controlled trial--oral washes (20 patients) versus test (19 patients)--, we have studied the effects of AM3 (a new oral BRM) on clinical evolution of the recurrent stomatitis (RAS) syndrome. The results obtained at 6th month showed significant decreases on ulcer numbers (p less than 0.001) as well as in their mean duration time (p less than 0.001) due to the AM3 treatment. From a pathophysiologic point of view, the study of the NK peripheral blood cells (Leu 11/CD16) suggests the existence of two kinds of RAS-patients: those showing normal NK cell numbers (approximately 33%) and those ones showing a partial lack in the NK numbers (approximately 67%). These results suggest different rational new approaches to treatment, based on new pathophysiological concepts.
 ...
PMID:[AM3 (a biological response modifier) in the treatment of recurrent aphthous stomatitis. Clinical evaluation and preliminary studies on NK (CD16) cells and their pathogenic role in the syndrome]. 183

Despite many attempts to find reliable in vitro criteria for the efficacy of Biological Response Modifiers--BRMs (immunomodulators, paramunity inducers) animal challenge models are still the only way to demonstrate the totality of interlocking defense mechanisms. Challenge models with mouse pathogenic viruses provide an excellent possibility to study protective effects of BRMs against acute or chronic forms of viral diseases. For comparative studies two completely different virus challenge models--Pseudorabies PR and Stomatitis Vesicularis VSV--were developed with adult and baby NMRI mice respectively. The potency of BRMs in preventing lethal disease reveals significant differences depending upon the sort of BRM, the route of application and the time of pretreatment. Defense mechanisms important for the control of Pseudorabies virus infection in adult NMRI mice were tested in vitro (ex vivo) and correlated well with the degree of protection in vivo. Comparison of BRM efficacy in selective viral challenge models combined with screening of a variety of antiviral defense functions in infected animals in vitro provide reliable methods in demonstrating the potency of BRMs against viral infections.
 ...
PMID:Tests on protection against viral diseases. 243 29